These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30548822)

  • 1. Male patients with a higher frequency of nocturnal urinary episodes are more likely to benefit from alpha-blocker therapy for bothersome nocturia.
    Lee CL; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O174-O179. PubMed ID: 30548822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms.
    Bae WJ; Bae JH; Kim SW; Chung BH; Kim JH; Kim CS; Lee HM; Lee KS; Yoo TK; Kim SI; Byun SS; Lee JY
    J Urol; 2013 Jul; 190(1):180-6. PubMed ID: 23357213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression.
    Gravas S; Manuel-Palacios J; Chavan C; Roehrborn CG; Oelke M; Averbeck MA; Biswas A; García LM; Mohamed K; Cortes V
    Prostate Cancer Prostatic Dis; 2024 Sep; 27(3):469-477. PubMed ID: 37794168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms.
    Shin YS; Zhang LT; Zhao C; Kim YG; Park JK
    Clin Interv Aging; 2014; 9():1021-30. PubMed ID: 25031529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study.
    Lojanapiwat B; Permpongkosol S
    Int Braz J Urol; 2011; 37(4):468-76. PubMed ID: 21888698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evaluation of nocturia in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and the analysis of the curative effect after medical or placebo therapy for nocturia: a randomized placebo-controlled study.
    Xue Z; Lin Y; Jiang Y; Wei N; Bi J
    BMC Urol; 2018 Dec; 18(1):115. PubMed ID: 30545338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality.
    Gorgel SN; Sefik E; Kose O; Olgunelma V; Sahin E
    Int Braz J Urol; 2013; 39(5):657-62. PubMed ID: 24267123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.
    Yoshida M; Sugiyama Y; Masunaga K; Maeda Y; Satoji Y; Nagata T; Inadome A
    Drugs Today (Barc); 2007 Jun; 43 Suppl B():1-7. PubMed ID: 17612712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The α1 adrenoceptor antagonist tamsulosin for the treatment of voiding symptoms improves nocturia and sleep quality in women.
    Kim SO; Choi HS; Kwon D
    Urol J; 2014 Jul; 11(3):1636-41. PubMed ID: 25015610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms.
    Cho S; Kwon SS; Lee KW; Yoo TK; Shin DG; Kim SW; Bae JH; Choi H; Kim YH
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28508455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The change of IPSS 7 (nocturia) score has the maximum influence on the change of Qol score in patients with lower urinary tract symptoms.
    Choi WS; Son H
    World J Urol; 2019 Apr; 37(4):719-725. PubMed ID: 30073391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zolpidem pharmacotherapy combined with alpha-blocker therapy for nocturia unresponsive to alpha-blocker monotherapy in men with lower urinary tract symptoms: a preliminary study.
    Song YS; Ku JH
    Int Urol Nephrol; 2007; 39(4):1147-52. PubMed ID: 17610040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nocturia improvement in the combination of Avodart(®) and tamsulosin (CombAT) study.
    Oelke M; Roehrborn CG; D'Ancona C; Wilson TH; Castro R; Manyak M
    World J Urol; 2014 Oct; 32(5):1133-40. PubMed ID: 24804842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostatic urethral angle might be a predictor of treatment efficacy of α-blockers in men with lower urinary tract symptoms.
    Hou CP; Chen CL; Lin YH; Tsai YL; Chang PL; Juang HH; Tsui KH
    Drug Des Devel Ther; 2014; 8():937-43. PubMed ID: 25075177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.